Skip to content

Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly (Clinical Trial)

Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04724954
Enrollment
6
Registered
2021-01-26
Start date
2019-03-01
Completion date
2019-12-31
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stroke

Keywords

acute stroke, sub-acute stage

Brief summary

The research project is intended to provide information pertaining to the usability, feasibility and clinical benefit of the BAC system for early sub-acute post CVA rehabilitation, improved cognition and emotive state while in acute inpatient rehabilitation settings (Kessler Foundation) and in an outpatient clinic at the same research hospital. The randomised controlled trials will take place at Kessler Foundation (West Orange, NJ). It will develop a new longitudinal therapy for elderly stroke survivors who are inpatients and then outpatients at a regional rehabilitation hospital, by adding BAC training to customary care for both inpatients and outpatients. Two systems will be used, improving continuity of care (one each for inpatient and outpatient settings).

Detailed description

This study targets participants, who had suffered a stroke very recently, who may or may not have been diagnosed with mild cognitive impairments or dementia (including Alzheimer's disease). It is important to find out if these improvements can be obtained with the computer game-based integrative (motor-cognitive) bimanual rehabilitation developed by Bright Cloud International Corp, and if these gains transfer to daily activities. The study also aims at determining benefit of continuum care training on the BAC in addition to conventional rehabilitation for participants who are inpatients and then outpatients at a rehabilitation hospital and clinic. Specific aims are: BAC technology acceptance (all groups); improved motor function for upper extremity; strengthening shoulder and fingers increased range of motion for arms and fingers; improved independence in activities of daily living; improved cognition; improved emotive state; reduction in perceived upper body pain. Another component of the research project is a small pilot targeting individuals with Parkinson's disease. For them the project is going to: determine technology acceptance when using the BrightBrainer system; benefit to arms motor function and strengthening when playing BCI therapeutic games; benefit to reduction or tremor when playing games; cognitive benefits improvement in their well-being.

Interventions

DEVICERehabilitation Therapy on Experimental Robotic Table and standard of care

Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation

GENETICRehabilitation Therapy as part of Standard of Care (Control)

Control group will receive Standard of Care training only

Sponsors

Kessler Foundation
CollaboratorOTHER
National Institute on Aging (NIA)
CollaboratorNIH
Bright Cloud International Corp
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Number of subjects: The Investigators expect to enroll up to 40 subjects, inpatients and then outpatients at a research hospital and its outpatient clinic at Kessler Foundation: 20 stroke patients, and 20 will be their spouses/caregivers of subjects participating in the randomized control trials component of this study.

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

(general) * Age 50 to 85; * Healthy age-matched volunteers * diagnosis of CVA that occurred more than 5 days prior and less than 21 days prior (for the stroke survivors group); * English speakers; * UE unilateral or bilateral involvement (from new bilateral CVA) * motor involvement (FMA score 20 to 45); * ability to actively move UE more than 10o for shoulder and elbow flexion/extension; * ability to actively extend fingers at least 5o * cognitive skills to participate (Montreal Cognitive Assessment (MoCA) \[Nasreddine et al 2005\] score 10-30). * The adaptive nature of BBC system hardware and therapeutic games can compensate for the motor limitations due to other co-morbidities. Therefore potential participants will not be excluded due to co-morbidities such as Parkinson or arthritis. Subjects may have normal cognition, MCI or dementia, since the games can compensate for diminished cognition through built-in cues and instructions. * Inclusion Criterion for the controlled clinical trials arm at Kessler Foundation • Living within 25 miles radius of Kessler Foundation West Orange location. This will facilitate participation in the outpatient clinic training, which follows inpatient rehabilitation. *

Exclusion criteria

. (general) * being younger than 50 or older than 85 years of age * previous stroke * Stroke that occurred more than 20 days prior to enrolment * Inability to actively extend fingers at least 5 degrees; v. 7/8/2018 * Fugl-Meyer scores of 19 or less; * severe visual neglect or legally blind * severe hearing loss or deafness * receptive aphasia or severe expressive aphasia; * severe spasticity (Modified Ashworth Scale 4/4) * contractures of the upper limb joints * uncontrolled hypertension (\>190/100 mmHg) * severe cognitive impairment determined by Montreal Cognitive Assessment (MoCA) \[Nasreddine et al, 2005\] test of 9 and below; * No chemodenervation or nerve block to upper limb involved during the experimental period (e.g., botulinum toxin injection) * inability to speak English; * a history of violence or drug abuse. * paranoia and psychotic behaviour. * inability participate in the neuropsychological pre-study assessment for reliable scores (e.g., cognitive impairment, communication disorders).

Design outcomes

Primary

MeasureTime frameDescription
Change in Fugl-Meyer Assessment score for upper extremity function (UE sub-set)Change between baseline, at 3 weeks and at 5 weeks post enrollmentUpper Extremity Mobility and function. It is scored from 0 (minimum score) to 66 (maximum). The higher the score, the better, with 66 indicating normal upper extremity function.
Change in Cognitive executive function assessment scoreChange between baseline, at 3 weeks and at 5 weeks post enrollmentTrail Making Test B (TMT-B), Neuropsychological Assessment Battery (NAB) Executive Functioning Module. This is a timed test (seconds) with less time indicative of better executive function. No scale.

Secondary

MeasureTime frameDescription
Change in CAHAI 9 Score of independence in bimanual ADLsChange between baseline, at 3 weeks and at 5 weeks post enrollmentChedoke Arm and Hand Activity Inventory, reflecting ADL independence in simulated bimanual ADLs. It consists of 9 tasks, each scored from 1 to 7, where 1 indicates need for total assistance (typical of very weak arms) to 7 indicating total independence in the task. Score range is 9 (minimum) to 63 (maximum)
Average game difficulty levels per sessionthrough study completion, an average 5 weeks from enrollmentBrightBrainer game difficulty averaged for all games played in a session. Higher average difficulty is indicative of higher function with 1 (easiest) to 10 (hardest). Higher average game difficulty represents a better outcome.
Participants' feedback through subjective evaluation of the systemat 3 weeks and at 5 weeks post enrollmentSubject feedback and overall ratings on BrightBrainer games, rated on a Likert scale with 1 being least desirable (strongly disagree) to 5 being most desirable rating (strongly agree).
Change in Verbal attention as measured by the Neuropsychological Assessment BatteryChange between baseline, at 3 weeks and at 5 weeks post enrollmentAttention module digit span tests verbal attention when subject is spoken a sequence of digits, then asked to repeat that sequence. Subjects is spoken 10 sequences of increasing length of digits (between 1 and 9). Score is 1 if sequence is repeated correctly, 0 otherwise. Min score 0 means no spoken digit sequence was repeated correctly, 10 is maximum score, all sequences were repeated correctly by subject.
Change in visual attention as measured by Neuropsychological Assessment BatteryChange between baseline, at 3 weeks and at 5 weeks post enrollmentVisual attention measured with the dots test of the Neuropsychological Assessment Battery (NAB). This is a delayed recognition span paradigm, in which an array of dots is exposed for a brief period, followed by a blank interference page, followed by a new array with one additional dot. The subject needs to point to the new dot. Test administered 3 times, minimum score 0 (none of the new dots found) to maximum 3 (all 3 new dots found).
Change in Beck Depression Inventory II (BDI II) score, a measure of depression severityChange between baseline, at 3 weeks and at 5 weeks post enrollmentparticipants' depression measure with higher scores indicating higher severity (worse mood). Score range is 0 to 63, with 0 indicating normal mood (no depression), 1-13 minimal depression, 14-19 mild depression, 20-28 for moderate and 29-63 severe depression.
Caregiver evaluation of experimental systemat 5 weeks from enrolmentRating of system perceived benefit to the person the caregiver cares for. Rating uses a Likert scale with 1 being least desirable outcome and 5 most desirable one.
Change in Arm Range of MotionChange between baseline, at 3 weeks and at 5 weeks post enrollmentMeasurement of active movement range for shoulder, elbow, and wrist. Measured with a mechanical goniometer, higher angular values indicating larger movement range.
Change in Grasp strength for whole hand (power grasp) and finger pinchChange between baseline, at 3 weeks and at 5 weeks post enrollmentGrasp strength and pinch strength measurements using dynamo-meter and pinch meter, respectively. Measured three times for maximal exertion, then averaged. Higher values are better, indicating less hand weakness.
Change in Finger Range of Motion measured with mechanical goniometerChange between baseline, at 3 weeks and at 5 weeks post enrollmentfinger extension/flexion range for proximal-metacarpal joints. Measured with mechanical goniometer
Change in Upper extremity functional index (UEFI-20) of independence in activities of daily livingChange between baseline, at 3 weeks and at 5 weeks post enrollmentSelf report of degree of independence in activities of daily living (ADLs). Consists of 20 questions, each scored on a 5 point scale with 0 complete dependence (unable to perform task) to 4 independence in a tasks. Minimum score is 0 (subjects is unable to perform any of the 20 listed tasks to 80 complete independence in all 20 ADLs. Higher score is better outcome.
Change in Stroke Impact Scale (SIS) measuring impact of stroke on independence in daily activitiesChange between baseline, at 3 weeks and at 5 weeks post enrollmentSelf report of degree of independence in activities of daily living (ADLs). Consists of questions, each scored on a 5 point Likert scale with 1 complete dependence (unable to perform task) to 5 independence in a tasks. Minimum score is 0 (subjects is unable to perform any of the 20 listed tasks to 80 complete independence in all 20 ADLs.
Game % Score (baseline and performance) in therapeutic gamesthrough study completion, an average 5 weeks from enrollmentBrightBrainer game performance %, with each game being scored individually. Scores converted to % of task achieved with range of 0% (worst outcome) to 100% (best outcomes).
Game difficulty levelsthrough study completion, an average 5 weeks from enrollmentBrightBrainer game difficulty settings, indicating game play intensity and challenge. Each game has levels from 1 (easiest) to 10 (hardest). Higher difficulty the subjects is able to play a game at represents a better outcome.

Other

MeasureTime frameDescription
Change in score for Boston Naming Test of naming objectsChange between baseline, at 3 weeks and at 5 weeks post enrollmentBoston naming test uses line drawings of objects of graded difficulty. Subject is ask to name (i.e. find nouns associated with) the object depicted in the line drawings. Scoring is based on how many objects (out of 80) were correctly named. Higher score means better cognitive function.
Blood pressure measured with medical meterthrough study completion, an average 5 weeks from enrollmentSystolic and Diastolic Blood pressures measured before, mid way and at end of every experimental session.
Heart rate measured with medical meterthrough study completion, an average 5 weeks from enrollmentHeart rate measured before, mid way and at end of every experimental session.
Change in cognitive function as measured by the Montreal Cognitive Assessment Test scoreChange between baseline, at 3 weeks and at 5 weeks post enrollmentMontreal Cognitive Assessment (MoCA) is a standardized test of cognitive function. It consists of question in several cognitive domains and has a maximum score of 30. Cognitive function is considered normal for scores above 26, with scores below 18 being indicative of severe cognitive impairments. Higher score is better.
Change in visuospatial memory as measured by Brief Visuospatial Memory Test, Revised (BVMT-R)Change between baseline, at 3 weeks and at 5 weeks post enrollmentBrief Visuospatial Memory Test, Revised (BVMT-R) is a measure of visuospatial memory. In three Learning Trials, the subject views a stimulus page showing an geometric figure for 10 seconds, and there are 6 drawings presented. Then the subject is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Last, a Recognition Trial, in which the respondent is asked to identify which of 12 figures were included among the original geometric figures, is administered. Raw scores will be used, with higher numbers representing better outcomes. Raw score range is 0 (worst outcome) to 6 (best outcome)
Change in Verbal memory as measured by Hopkins Verbal Learning Test, RevisedChange between baseline, at 3 weeks and at 5 weeks post enrollmentHopkins Verbal Learning Test, Revised (HVLT-R) is a measure of verbal memory. It provides a brief assessment of immediate recall, delayed recall and delayed recognition. Subject is read a series of nouns in several categories, and the asked t repeat these nouns by writing them on a piece of paper. The test is repeated three times, and each time the score is a count of how many nouns were remembered by the subject. The second phase of the test involves delayed recall, which is administered after about 20 minutes from the original test. subject needs to write down all the nouns they remembered and these are counted. There is a maximum of 12 correct responses during delayed recall, so max score is 12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026